Medication info

Linagliptin Metformin Duo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
Bright orange oval-shaped film-coated tablets with a double convex surface
Packaging
60 tablets/box [(10 tablets/PTP x 6)]
Approval status
Expired

MFDS item code 202001485 · Approved 2020.03.03

This product's status changed to Expired on 2025.03.03. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Who Require Careful Administration). 5. Patients whose blood glucose is not adequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Who Require Careful Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Receive This Medicine).

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood glucose control
View approved original text

This drug is used together with diet and exercise therapy to help control blood glucose levels in adults with Type 2 diabetes. It may be administered when there is no experience with diabetes drug treatment or if blood glucose control is difficult with monotherapy. It is also an alternative or used in combination when metformin monotherapy or linagliptin and metformin combination therapy do not provide sufficient efficacy. It can be used as an adjunct when blood glucose control is difficult while using sulfonylureas, insulin, or empagliflozin. This drug helps improve blood glucose control in various therapeutic combinations.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Who Require Careful Administration). 5. Patients whose blood glucose is not adequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Who Require Careful Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Receive This Medicine).

Precautions

This drug helps control blood glucose levels. However, during treatment, there is a risk of serious adverse effects such as lactic acidosis, which requires caution. Lactic acidosis occurs when there is an excessive buildup of lactic acid in the body, and if untreated, it can be life-threatening. This drug should not be administered to certain patients. For example, those who are allergic to any ingredient in this drug, patients with Type 1 diabetes, severe renal impairment, acute myocardial infarction, heart failure, liver dysfunction, acute alcohol intoxication or alcoholism, pregnant women, or breastfeeding mothers should not take this drug. There is a risk of hypoglycemia, so blood glucose levels should be closely monitored, especially when taking medications such as insulin or sulfonylureas. Immediate action is necessary if hypoglycemic symptoms occur. Patients with impaired renal function should undergo renal function tests before taking this drug and regularly monitor renal function during treatment. If renal function declines severely, this drug should be discontinued. Patients with weak heart function need to be cautious while taking this drug and periodically check cardiac and renal function. If a patient receives iodinated contrast agents used in radiological examinations, this drug should be temporarily discontinued before and after the examination, and resumed only after renal function has stabilized. Patients scheduled for surgery should stop taking this drug 48 hours before surgery and can resume after renal function has recovered post-surgery. Acute pancreatitis or bullous skin diseases may occur during treatment, so if persistent and severe abdominal pain or skin abnormalities occur, consult a doctor immediately. The metformin component can lower vitamin B12 levels, so checking for vitamin B12 deficiency regularly during long-term use is advisable. This drug may interact with other medications, so it is essential to inform your physician or pharmacist about any other medications being taken, especially when using drugs that affect renal function. It is advisable for pregnant women or those planning to become pregnant to avoid taking this drug and to refrain from use while breastfeeding. Safety and efficacy have not been sufficiently established for children under 10 years and adolescents aged 10 to 17 years, so use is not recommended. Elderly patients are likely to have reduced kidney function, so renal function should be evaluated and monitored regularly before starting this drug. In cases of overdose, there is a risk of lactic acidosis, and if suspected, medical attention should be sought immediately. This drug should be stored in a sealed container to avoid exposure to air or moisture, and stored at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness.

Side effects

  • pharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • lactic acidosis
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 125 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • diarrhea
  • hypoglycemia
  • acute pancreatitis
  • bullous pemphigoid
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • headache
  • drowsiness
  • chest discomfort
  • asthenia
  • pruritus
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased blood creatinine
  • facial edema
  • back pain
  • osteoarthritis
  • limb pain
  • myositis
  • myalgia
  • hair loss
  • dermatitis
  • anxiety
  • confusional state
  • nocturia
  • skin lesions
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to air and moisture and must be kept in a sealed container. Additionally, it is important to store it at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Bright orange oval-shaped film-coated tablets with a double convex surface

Package unit

60 tablets/box [(10 tablets/PTP x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.